Nahdi Medical Company (4164) fair value: what the stock is really worth
As of Nov 8, 2026: fair value (intrinsic value) of Nahdi Medical Company stock SAR 113, price SAR 91.00, upside +24.4%, quality 68 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
55‑month range 82.00 SAR – 173.06 SAR · fair‑value band 84.91 SAR – 150.14 SAR · the 91.00 SAR price screens below the 113.21 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Nahdi Medical in your weekly email
Every Wednesday you see whether Nahdi Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nahdi Medical Company, together with its subsidiaries, engages in the wholesale and retail trading of cosmetics, pharmaceutical, special and healthy foods, and medical equipment products in the Kingdom of Saudi Arabia and the United Arab Emirates.
Show moreShow less
The company also offers mom and baby, beauty, and everyday essentials through retail and online stores. In addition, it operates Nahdi Care polyclinic; and provides virtual care services. Further, the company is involved in operating E-Pharmacist platform; and Nahdi Online, an online pharmacy.
Additionally, it provides labor and IT consulting services. Nahdi Medical Company was incorporated in 1986 and is headquartered in Jeddah, the Kingdom of Saudi Arabia.
Stock analysis
Nahdi Medical Company (4164) currently trades at 91.00 SAR, while our model-based Fair Value estimate is 113.21 SAR, implying the stock looks roughly 20% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 128.11 SAR per share, and 18 of the 26 models we run sit above the 91.00 SAR price.
Bear case: the Asset-Based group reads lowest at 13.79 SAR, and 8 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 84.91 SAR (bear) to 150.14 SAR (bull), the price of 91.00 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Nahdi Medical Company reported revenue of 10.2B SAR in FY2025 versus 8.1B SAR in FY2021, a compound +6.1%/yr. Reported net income was 831M SAR in FY2025, compounding +0.6%/yr from FY2021.
Key figures
Market cap 11.8B SAR (≈ $3.2B) Mid · P/E ratio 15.0 · P/S ratio 1.10 · EPS (TTM) 6.06 SAR · Dividend yield 3.3% · Net margin 7.4% · Return on equity 30.7% · Return on assets (EBIT) 17.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 24%, 4164 screens cheaper than that median.
Fair Value models
Bear84.91 SARFair Value 113.21 SARBull150.14 SAR
Price 91.00 SAR · Upside +24.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.62 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.4%
Dividend (yield on the price)3.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 9%
Growth Forecast
Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Saudi Arabia: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about −0.8% a year for the price and +4.0% for the forecasts.
AI conclusion: Nahdi benefits from a debt-free balance sheet and strong cash conversion supporting solid returns, yet shows limited signals of a qualitative moat while expanding operations.
Main risk: Continued investment in new healthcare services and digital channels risks weighing on earnings if costs keep rising faster than profits and scale gains remain limited.
Nahdi is pushing hard into healthcare services, regional clinics and digital channels, which lifted nine-month revenue 7 percent but squeezed gross margins as costs for these initiatives rose faster than profits. The nine-month net profit fell nearly 5 percent year over year despite the top-line gains. Will the new segments eventually deliver enough scale and mix improvement to restore margins, or will the investment drag continue to weigh on earnings?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+24.4% · Below median
Profitability
Return on equity (12 months)30.7% · Top 25%
Return on assets12.4% · Top 25%
Net margin (12 months)7.4% · Top 25%
Operating margin (12 months)7.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)9.4% · Above median
Dividend yield (12 months)3.3% · Above median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (12 months)15.0× · Cheapest 25%
P/B4.31× · Priciest 25%
P/S (12 months)1.10× · Priciest 25%
Price / free cash flow (fiscal year)14.7× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nahdi Medical Company Fair Value". https://www.fairvalue-calculator.com/stock/4164
Frequently asked questions
Is Nahdi Medical Company (4164) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 113.21 SAR versus a price of 91.00 SAR, about +24% upside (undervalued).
What is the fair value of 4164?
Our model-based fair value for Nahdi Medical Company is 113.21 SAR (as of Nov 8, 2026), built from audited fundamentals. The current price: 91.00 SAR.
What is the quality score of 4164?
Nahdi Medical Company has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nahdi Medical Company (4164)?
Our model-based price target is the fair value of 113.21 SAR (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 84.91 SAR, optimistic scenario 150.14 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Nahdi Medical Company stock forecast for 2026?
Our models put fair value at 113.21 SAR, about +24% upside versus a price of 91.00 SAR (undervalued). Cautious scenario 84.91 SAR, optimistic scenario 150.14 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Nahdi Medical Company (4164)?
Nahdi Medical Company reported trailing-twelve-month revenue of about 10.7B SAR (latest available figure, as of Nov 8, 2026).
Does Nahdi Medical Company pay a dividend?
Nahdi Medical Company currently shows a dividend yield of 3.30% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Nahdi Medical Company (4164) and when is the ex-dividend date?
Nahdi Medical Company pays a dividend of 3.00 SAR per share a year, a dividend yield of 3.3%. The last ex-dividend date was Aug 16, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 49.5% of earnings. Free cash flow covers the dividend 2.07 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Nahdi Medical Company (4164)?
For today's price to be fair in a discounted-cash-flow model, Nahdi Medical Company would have to grow free cash flow by +1.2 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 4164 use?
Our models discount Nahdi Medical Company at 9.0 %: a base by market capitalisation (mid), damped by beta 0.11, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nahdi Medical Company that is +1.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Nahdi Medical Company (4164) delivered so far?
Over the past 5 years revenue at Nahdi Medical Company grew +3.4 % a year. The price currently implies free-cash-flow growth of +1.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nahdi Medical Company (4164) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Nahdi Medical Company (+1.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nahdi Medical Company (4164)?
The free-cash-flow yield on the price is 6.82 %: that much free cash flow Nahdi Medical Company produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nahdi Medical Company (4164)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nahdi Medical Company it is 113.21 SAR per share (as of Nov 8, 2026), against a price of 91.00 SAR. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Nahdi Medical Company stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 4164 trades below its calculated fair value: price 91.00 SAR, fair value 113.21 SAR, a gap of about +24% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4164?
No. The price is what the market pays today (91.00 SAR); the fair value is what the company's own numbers justify (113.21 SAR). For Nahdi Medical Company the two are 22.21 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Nahdi Medical Company worth?
The market values Nahdi Medical Company at about 11.8B SAR (market capitalisation, as of Nov 8, 2026). Per share that is 91.00 SAR; our models calculate a fair value of 113.21 SAR per share.
What do the bullish and bearish scenarios say about 4164?
Our models span a range for Nahdi Medical Company: cautious scenario 84.91 SAR, base 113.21 SAR, optimistic 150.14 SAR per share (as of Nov 8, 2026, price 91.00 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4164?
Nahdi Medical Company trades at a price-to-earnings ratio of 15.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 113.21 SAR is built from several models across several years. Other multiples: P/B 4.3, P/S 1.1, EV/EBITDA 9.1.
How solid is the balance sheet of Nahdi Medical Company (4164)?
Balance-sheet figures for Nahdi Medical Company (as of Nov 8, 2026): return on equity 30.7%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 4164 from its 52-week high?
Nahdi Medical Company trades at 91.00 SAR, about 14% below its 52-week high of 106.23 SAR and 11% above the low of 82.00 SAR (as of Nov 8, 2026). Distance from the high says nothing about value: that is what the fair value of 113.21 SAR is for.
Which stocks are comparable to Nahdi Medical Company?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nahdi Medical Company stock attractive at the current price?
The data as of Nov 8, 2026: price 91.00 SAR, calculated fair value 113.21 SAR (+24%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4164 calculated?
We run Nahdi Medical Company through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 113.21 SAR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Nahdi Medical Company currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nahdi Medical Company (4164)?
The closing price on Nov 8, 2026 was 91.00 SAR. Our model-based fair value is 113.21 SAR, about +24% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nahdi Medical Company right now?
Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Nahdi Medical Company
How large is the market capitalisation of Nahdi Medical Company (4164)?
The market capitalisation of Nahdi Medical Company is 11.8B SAR (≈ $3.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nahdi Medical Company (4164)?
The price-to-sales ratio of Nahdi Medical Company is 1.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nahdi Medical Company (4164)?
Earnings per share at Nahdi Medical Company are 6.06 SAR (price ÷ EPS = P/E 15.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Nahdi Medical Company (4164)?
The dividend yield of Nahdi Medical Company is 3.3% (payout 49.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Nahdi Medical Company (4164)?
The net margin of Nahdi Medical Company is 7.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nahdi Medical Company (4164)?
The return on equity (ROE) of Nahdi Medical Company is 30.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nahdi Medical Company (4164)?
On an EBIT basis the return on assets of Nahdi Medical Company is 17.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nahdi Medical Company (4164)?
The operating margin of Nahdi Medical Company is 7.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nahdi Medical Company (4164)?
Revenue at Nahdi Medical Company is growing +9.4% versus a year earlier (3y avg +5.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nahdi Medical Company (4164)?
Earnings per share at Nahdi Medical Company are growing +6.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nahdi Medical Company (4164) carry?
The net debt of Nahdi Medical Company is 1.2B SAR (fiscal year 2025, ≈ 1.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nahdi Medical Company in the live analysis
One click puts Nahdi Medical Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026